Oral Abstracts 7: RA ClinicalO37. Long-Term Outcomes of Early RA Patients Initiated with Adalimumab Plus Methotrexate Compared with Methotrexate Alone Following a Targeted Treatment Approach by Fleischmann, Roy et al.
Thursday 25 April 2013, 09.00–10.30
BSR AND BHPR ORAL PRESENTATION OF ABSTRACTS
ORAL ABSTRACTS 7: RA CLINICAL
O37. LONG-TERM OUTCOMES OF EARLY RA PATIENTS
INITIATED WITH ADALIMUMAB PLUS METHOTREXATE
COMPARED WITH METHOTREXATE ALONE FOLLOWING A
TARGETED TREATMENT APPROACH
Roy Fleischmann1, Ronald F. van Vollenhoven2, Josef Smolen3,
Paul Emery4, Stefan Florentinus5, Suchitrita Rathmann6,
Hartmut Kupper7 and Arthur Kavanaugh8
1Rheumatology, University of Texas Southwestern, Dallas, TX, USA,
2Rheumatology, Karolinska Institute, Stockholm, Sweden, 3Institute
of Rheumatology, Medical University of Vienna and Hietzing Hospital,
Vienna, Austria, 4Musculoskeletal Disease, Leeds Teaching Hospital,
Leeds, UK, 5Rheumatology Medical Affairs, AbbVie, Rungis, France,
6Data and Statistical Sciences, AbbVie, North Chicago, IL, USA,
7Immunology Development, AbbVie GmbH and Co. KG,
Ludwigshafen, Germany and 8Rheumatology, Allergy and
Immunology, University of California San Diego, La Jolla, CA, USA
Background: This analysis assessed, on a group level, whether there
is a long-term advantage for early RA patients treated with
adalimumab (ADA)þMTX vs those initially treated with placebo
(PBO)þMTX who either responded to therapy or added ADA following
inadequate response (IR).
Methods: OPTIMA was a 78- week, randomized, controlled trial of
ADAþMTX vs PBOþMTX in MTX-naı¨ve early (<1 year) RA patients.
Therapy was adjusted at week 26: ADAþMTX-responders (R) who
achieved DAS28 (CRP) <3.2 at weeks 22 and 26 (Period 1, P1) were
re-randomized to withdraw or continue ADA and PBOþMTX-R
continued randomized therapy for 52 weeks (P2); IR-patients received
open-label (OL) ADAþMTX during P2. This post hoc analysis
evaluated the proportion of patients at week 78 with DAS28 (CRP)
<3.2, HAQ-DI <0.5, and/or mTSS 0.5 by initial treatment. To
account for patients who withdrew ADA during P2, an equivalent
proportion of R was imputed from ADAþMTX-R patients.
Results: At week 26, significantly more patients had low disease
activity, normal function, and/or no radiographic progression with
ADAþMTX vs PBOþMTX (Table 1). Differences in clinical and
functional outcomes disappeared following additional treatment,
when PBOþMTX-IR (n¼348/460) switched to OL ADAþMTX.
Addition of OL ADA slowed radiographic progression, but more
patients who received ADAþMTX from baseline had no radiographic
progression at week 78 than patients who received initial PBOþMTX.
Conclusions: Early RA patients treated with PBOþMTX achieved
comparable long-term clinical and functional outcomes on a group
level as those who began ADAþMTX, but only when therapy was
optimized by the addition of ADA in PBOþMTX-IR. Still, ADAþMTX
therapy conferred a radiographic benefit although the difference did
not appear to translate to an additional functional benefit.
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O38. 24-WEEK RESULTS OF A BLINDED PHASE IIB
DOSE-RANGING STUDY OF BARICITINIB, AN ORAL JAK1/
JAK2 INHIBITOR, IN COMBINATION WITH TRADITIONAL
DMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS
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Background: BaBaricitinib (formerly LY3009104/INCB028050), a
novel, oral inhibitor of JAK1 and JAK2 in the JAK-STAT signaling
pathway, has been evaluated in a 24 week blinded phase IIb study in
patients with moderate to severe RA with inadequate response to
MTX.The primary endpoint after 12 weeks of treatment was met and
previously reported. The 24 week safety and efficacy findings are
reported here.
Methods: Patients with active RA (defined as at least 8 swollen and 8
tender joints based on the 66/68 joint assessment) on stable MTX were
randomized 2:1:1:1:1 to receive placebo (PBO) or 1of 4 once-daily
baricitinib doses (1, 2, 4, or 8 mg) for 12 weeks. Patients assigned to 2,
4 or 8 mg continued blinded treatment for an additional 12 weeks.
Patients assigned to placebo or 1 mg were reassigned to an
exploratory 4 or 2 mg BID group between weeks 12 and 24 and
were excluded from the primary 24-week analysis.
Results: Three hundred one patients entered the study. After 12
weeks of treatment, significant differences vs placebo were observed
in the proportion of patients achieving ACR20, ACR50 and ACR70,
DAS28CRP<2.6 (Table 1). At week 24, patients receiving 2 mg, 4 mg
or 8 mg baricitinib maintained or improved in all measures. Over 12
weeks in the PBO and combined baricitinib groups, there were similar
incidence rates of TEAEs (44% vs 41%), infections (12% vs 14%) and
SAEs (2% vs 2%, respectively) over 12 weeks. Over 24 weeks in the
2 mg, 4 mg and 8 mg groups, the rate of TEAEs was 60%, 62% and
72%, the rate of infections was 27%, 25% and 28% and the rate of
SAEs was 6%, 0 and 8%, respectively. There were no opportunistic
infections and no deaths. Decreases in hemoglobin and small
increases in serum creatinine were seen. Increases were seen in
LDL and HDL.
Conclusions: Significant improvements in the signs and symptoms of
RA vs placebo were observed over 12 weeks. These responses were
maintained or improved for an additional 12 weeks of blinded
TABLE 1. Week 78 clinical, functional, and radiographic outcomes in patients who received continued ADAþMTX vs those who continued PBOþMTX or added open-label
ADA following an inadequate response
ADAþMTX, n/N (%)a PBOþMTX, n/N (%)b
Outcome Week 26 Week 52 Week 78 Week 26 Week 52 Week 78
DAS28 (CRP) <3.2 246/466 (53) 304/465 (65) 303/465 (65) 139/460 (30)*** 284/460 (62) 300/460 (65)
HAQ-DI <0.5 211/466 (45) 220/466 (47) 224/466 (48) 150/460 (33)*** 203/460 (44) 208/460 (45)
mTSS 0.5 402/462 (87) 379/445 (86) 382/443 (86) 330/459 (72)*** 318/440 (72)*** 318/440 (72)***
DAS28 (CRP) <3.2þmTSS 0.5 216/462 (47) 260/443 (59) 266/443 (60) 112/459 (24)*** 196/440 (45) 211/440 (48)***
DAS28 (CRP) <3.2þHAQ-DI <0.5þmTSS 0.5 146/462 (32) 168/443 (38) 174/443 (39) 82/459 (18)*** 120/440 (27)*** 135/440 (31)**
aIncludes patients from the ADA Continuation (n¼ 105) and OL ADA Carry On (n¼259) arms, as well as the proportional equivalent number of responders from the ADA
Withdrawal arm (n¼ 102). bIncludes patients from the MTX Continuation (n¼ 112) and Rescue ADA (n¼ 348) arms. Last observation carried forward: DAS28 (CRP) and
HAQ-DI; Multiple imputations: mTSS. ***P< 0.001 and **iP< 0.01, respectively, for differences between initial treatments from chi-square.
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treatment with 2 mg, 4 mg and 8 mg. In addition, safety signals
observed over 12 and 24 weeks were consistent with previously
conducted studies of baricitinib.
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O39. TOCILIZUMAB MONOTHERAPY COMPARED
WITH ADALIMUMAB MONOTHERAPY IN RA: RESULTS
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Background: Tocilizumab (TCZ) efficacy as monotherapy for RA has
been assessed in 6 trials. ADACTA is the first trial to determine
superiority of 1 approved biologic vs another [TCZ vs adalimumab
(ADA)] as monotherapy.
Methods: ADACTA was a phase IV randomized, double-blind, 24-
week study in patients with RA 6-mo duration, DAS28 >5.1, who
were MTX intolerant or MTX was ineffective/inappropriate. Patients
received TCZ 8 mg/kg i.v. every 4 weeks (þ PBO ADA) or ADA 40 mg
SC every 2 weeks (þ PBO TCZ) for 24 weeks. Primary endpoint was
mean change from BL in DAS28 at 24 weeks.
Results: ITT population was 325 patients (163 TCZ/162 ADA).
Mean BL characteristics were similar in TCZ and ADA arms: age
(54.4/53.3 y), RA duration (7.3/6.3 y), DAS28 (6.72/6.76). At week 24
(Table 1), mean change from BL in DAS28 was significantly greater
with TCZ than ADA (P< 0.0001). Statistically significantly greater
proportions of TCZ than ADA patients achieved DAS28 <2.6, DAS28
3.2 and ACR20/50/70 responses (P<0.005). A difference in favour of
TCZ was observed in proportions of patients achieving CDAI and SDAI
remission (2.8 and 3.3) at week 24 (post hoc analysis; P<0.05).
From week 16, the proportion of patients achieving ACR/EULAR
remission was numerically greater with TCZ and by week 24 was 18%
vs 11% for ADA. For exploratory endpoints HAQ-DI, SF-36 MCS, SF-
36 PCS and FACIT Fatigue, differences in mean change from BL at
week 24 were numerically higher for TCZ than ADA. Adverse events
(AEs), serious AEs and serious infection were similar between arms
(TCZ, 82.1%/11.7%/ 3.1%; ADA, 82.7%/9.9%/ 3.1%). Transaminase,
LDL elevations and neutrophil count reductions were more common
with TCZ. 2 deaths occurred in the TCZ arm (1 sudden death,
1 reported illicit drug overdose).
Conclusions: TCZ monotherapy was superior to ADA monotherapy in
reducing RA signs/symptoms in MTX-intolerant patients/patients in
whom MTX was ineffective/inappropriate. Agents had similar overall
AE profiles. Lab changes were consistent with previous reports.
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TABLE 1. Results
PBO (n¼ 98) 1 mg QD (n¼ 49) 2 mg QD (n¼ 52) 4 mg QD (n¼ 52) 8 mg QD (n¼ 50)
% ACR20 at 12 weeks 41 57* 54* 75* 78*
% ACR50 at 12 weeks 10 31* 17 35* 40*
% ACR70 at 12 weeks 2 12* 8 23* 20*
%DAS28CRP< 2.6 at 12 weeks 4 14* 15* 37* 22*
%DAS28ESR< 2.6 at 12 weeks 1 4 8* 25* 16*
% ACR20 at 24 weeks – – 63 78 73
% ACR50 at 24 weeks – – 20 48 55
% ACR50 at 24 weeks – – 10 28 24
%DAS28CRP< 2.6 at 24 weeks – – 16 34 37
%DAS28ESR< 2.6 at 24 weeks – – 13 25 18
All values non-responder imputation and 1-sided P-value from Fisher’s exact test; *P< 0.05 vs PBO.
TABLE 1. Endpoints at week 24 (ITT populationa)
TCZ n¼ 163 ADA n¼ 162 Pb
Primary:  from BL in DAS28 –3.3c –1.8 (diff: –1.5) <0.0001
Secondary
DAS28 <2.6,% 39.9 10.5 <0.0001
DAS28 3.2,% 51.5 19.8 <0.0001
ACR20, % 65.0 49.4 0.0038
ACR50, % 47.2 27.8 0.0002
ACR70, % 32.5 17.9 0.0023
Exploratory and post-hoc endpoints
CDAI remission, % 17.2 9.3 0.0389d
SDAI remission, % 18.4 8.0 0.0067d
ACR/EULAR remission (Boolean), % 18.0 11.0 0.0569d
 from BL in HAQ-DI –0.7 –0.5 (diff:–0.2) 0.0653d
 Change. aLOCF and non-responder imputation applied to primary and secondary continuous and categorical endpoints respectively. bP-values adjusted for region,
duration of RA and for baseline. c2 TCZ patients (no post-baseline data) excluded. dP-value not adjusted for multiple testing/type 1 error therefore no significance claimed.
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Background: The availability of multiple biologic agents to treat RA
has created a need for comparative assessment. AMPLE (Abatacept
Vs Adalimumab Comparison in Biologic-Naı¨ve RA Subjects with
Background Methotrexate) is the first head-to-head study powered
to compare subcutaneous (SC) abatacept (ABA) and adalimumab
(ADA) on a background of MTX. Here, we report key 1-year data from
AMPLE, including ACR core component data.
Methods: AMPLE is an ongoing, Phase IIIb, randomized, investigator-
blinded study of 24 months’ duration with a 12-month primary efficacy
endpoint. Biologic-naı¨ve RA patients with an inadequate response to
MTX were randomized to 125 mg ABA weekly or 40 mg ADA bi-weekly,
in combination with MTX. The primary endpoint was non-inferiority (NI)
of ABA to ADA based on ACR 20 at 12 months; key secondary
endpoints were rates of radiographic non-progression, safety, injec-
tion-site reactions and retention. ACR core component data were also
analysed.
Results: A total of 646 patients were randomized and treated; 86.2%
of ABA patients and 82.0% of ADA patients completed 12 months.
Baseline characteristics were balanced across both arms (mean
DAS28-CRP of 5.5 and disease duration 1.8 years). At 1 year, 64.8%
of ABA patients and 63.4% of ADA patients achieved an ACR20
response, with an estimated difference between the two arms (95% CI)
of 1.8 (–5.6, 9.2) supporting NI of ABA to ADA. The kinetics of response
across ACR scores were comparable overall, with an ACR50 of 46.2%
and 46%, and ACR70 of 29.2%and 26.2% for ABA and ADA,
respectively, at 1 year. Responses in some ACR core components
were similar in ABA and ADA groups over time, although some
differences were observed. At 1 year, the rates of radiographic non-
progression were comparable, as were mean changes in van der
Heijde–modified total Sharp scores (0.58 vs 0.38 for ABA vs ADA). The
rates of adverse events (AEs), serious AEs, serious infections and
malignancies were comparable. There were more patients with
autoimmune AEs (3.1% vs 0.9%) in the ABA arm; however, none
were serious. One patient in each arm discontinued due to an
autoimmune event. There were fewer discontinuations with ABA due to
AEs (3.5% vs 6.1%) and due to serious infections (0% vs 1.5%).
Injection-site reactions occurred in significantly fewer ABA-treated
patients (3.8% vs 9.1%, P¼0.006).
Conclusions: This first head-to-head study in RA patients comparing
biologic agents on background MTX demonstrated that subcutaneous
abatacept is comparable to adalimumab by most efficacy measures,
including radiographic progression. Safety was generally similar, with
fewer discontinuations and injection-site reactions observed with
abatacept.
Disclosures: G.C., Pfizer Inc.—Research Support, Consultant Fees,
BMS, AstraZeneca—Consultant Fees. R.F., Genentech Inc., MSD,
BiogenIdec—Research Support, Roche, Abbott, Amgen, UCB, Pfizer,
BMS, Lilly, Sanofi-Aventis, Lexicon, Novartis, Astellas, AstraZeneca,
Janssen—Research Support, Consultant Fees, HGS—Consultant
Fees. M.M., BMS—Shareholder, Employee. M.S., BMS—Consultant
Fees, Abbott Laboratories—Speaker Bureau. R.V., UCB, Pfizer,
Novartis, Eli Lilly, Takeda, Centocor—Research Support. D.V.,
Abbott, Amgen, AstraZeneca, BMS, Centocor, Chugai, Eli-Lilly, GSK,
Merck, Novartis, Otsuka, Pfizer, Roche, Sanofi-Aventis, Schering-
Plough, UCB, Wyeth—Research Support, Imaging Rheumatology
bv—Owner. M.W., BMS—Research Support, Consultant Fees. C.Z.,
BMS—Shareholder, Employee.
O41. WHAT HAPPENS TO ACPA-POSITIVE PATIENTS
WITHOUT CLINICAL SYNOVITIS?
Chadi Rakieh1, Jacqueline L. Nam1, Laura Hunt1, Edith Villeneuve1,
Lesley-Anne Bissell1, Sudipto Das1, Philip Conaghan1,
Dennis McGonagle1, Richard J. Wakefield1 and Paul Emery1
1Division of Rheumatic and Musculoskeletal Disease,
LIMM, University of Leeds, Leeds, UK
Background: Rheumatoid arthritis (RA) is associated with autoanti-
bodies including anti-cyclic citrullinated peptide antibodies (ACPA)
which may be present years before clinical presentation. The aim of
the study was to investigate the pre-clinical phase of ACPA positive
patients with non-specific musculoskeletal symptoms and factors
associated with the development of inflammatory arthritis (IA).
Methods: Patients were recruited from rheumatology clinics and
primary care under the UKCRN portfolio. Clinical assessment and
investigations including ultrasound imaging of the hands and feet were
undertaken at baseline and 3–6 month intervals or at change of
symptoms. The end point was the development of clinical synovitis
(CS), defined as the presence of at least one tender and swollen joint.
A healthy control group was recruited and assessed using the same
biomarkers including imaging and serology.
Results: A total of 122 patients without a diagnosis of IA were studied.
At baseline 22 patients were found to have CS and hence were
excluded from analysis. One hundred patients (74% females) with a
median age of 51 years (24–77 years) had no CS at baseline. Median
duration of follow up was 12 months (1–50 months). Thirty-eight (38%)
patients developed CS after a median duration of 26.8 weeks (1–170
weeks); 33 patients met ACR EULAR 2010 criteria for RA and 5
patients were classified as undifferentiated IA. Nineteen of the 38
patients developed CS within 6 months of presentation; 12 patients
between 6 and 12 months, and 7 patients after 12 months.
At baseline, the mean ultrasound PD score of the controls (n-¼26)
was 0.39 (S.D. 0.2). In comparison with controls, the mean PD score
was 1.00 (S.D. 1.87, P 0.011) in patients who did not progress to CS
(n¼ 53), and 2.5 (S.D. 4.07, P 0.003) in patients who progressed
(n¼ 36).
Conclusions: The results of this prospective cohort indicate that
ACPA positive patients with non-specific musculoskeletal symptoms
are at high risk of developing IA within 1 year of presentation. These
patients represent a group with imminent RA who may be suitable for
interventional studies.
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Background: There is a growing appreciation of the role of neutrophils
in inflammatory diseases such as RA and JSLE. Neutrophils respond
to inflammatory stimuli through the production of reactive oxygen
metabolites and release of proteases, which can damage host tissue if
released inappropriately. Neutrophils also drive chronic inflammation
via the secretion of inflammatory molecules such as cytokines,
chemokines and leukotrienes. The aim of this study was to investigate
gene expression signatures which correlate with disease activity or
which may predict response to therapy in RA patients.
Methods: Neutrophils were isolated from the venous blood of RA
patients (n¼14) pre- and 12-weeks post-anti-TNF therapy, and from
healthy controls (n¼ 6). RNA was poly-A selected and sequenced on
the Illumina HiSeq 2000 platform using standard protocols. Reads
(50 bp, single-ended) were mapped to the human genome (hg19,
UCSC) using Tophat and differential expression analysis was carried
out using edgeR applying a 5% false discovery rate (FDR). Signalling
pathway analysis was carried out using Ingenuity Pathway Analysis
software (IPA). Interferon (IFN) signalling was confirmed by Western
blotting for phosphorylated STAT proteins in protein lysates.
Results: Pathway analysis of RNASeq data identified elevated
activation of IFN signalling in RA neutrophils (n¼14) compared with
healthy controls (n¼ 6). Specifically, IPA predicted that gene expres-
sion in RA neutrophils is regulated by IFN (P¼1.42E-35), IFNa
(P¼2.96E-28) and IFNb (1.75E-12). IPA also predicted activation of
STAT1 (P¼ 3.75E-19) and STAT3 (P¼1.02E-22) transcription factors
in RA neutrophils, and this was confirmed by Western blotting of
protein lysates. There was some heterogeneity in the level of
expression of IFN target genes amongst the entire group of RA
patients. However, patients who achieved a response to anti-TNF
therapy (DAS281.2, n¼ 11) measured at 12-weeks had signifi-
cantly higher expression of IFN target genes pre-therapy compared
with non-responders. Anti-TNF therapy resulted in a significant up-
regulation of IFN target genes in those patients who did not achieve a
EULAR response (DAS28<1.2, n¼ 3) over 12 weeks of anti-TNF
therapy.
Conclusions: RA neutrophils had a gene expression signature
indicative of activation in vivo by IFNs. This IFN gene expression
signature was more evident in patients who went on to achieve a
response to anti-TNF therapy. Moreover, IFN gene expression was
significantly up-regulated in anti-TNF non-responders by anti-TNF
therapy. IFN gene expression signatures have been reported in RA
patients in other cell types, but we believe this is the first account of an
IFN signature in RA neutrophils. Expression of IFN genes may be a
useful predictive marker of response to anti-TNF therapy in RA
patients, and we are currently investigating this in a larger cohort of
patients.
Disclosures: The authors have declared no conflicts of interest.
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O43. A PILOT STUDY EVALUATING RNA TRANSCRIPTION
PROFILES IN IDIOPATHIC INFLAMMATORY AND INCLUSION
BODY MYOSITIS: A NEXT GENERATION SEQUENCING
APPROACH
Philip Hamann1,2, James Heward2, Neil McHugh1,2 and
Mark A. Lindsay2
1Department of Rheumatology, Royal National Hospital for
Rheumatic Diseases, Bath and 2Department of Pharmacy and
Pharmacology, University of Bath, Bath, UK
Background: This pilot study investigates differences in RNA
expression in idiopathic inflammatory (IIM; anti- Jo-1 antibody positive)
and inclusion body myositis (IBM). Pathogenesis of IIM and IBM
remains poorly understood. Features of IIM and IBM are readily
identifiable clinically and histologically, and good evidence demon-
strates clinical associations with autoantibodies in IIM. Previous
work suggests several possible mechanisms in the development of
IIM and IBM. However, the complexity and relative rarity of these
conditions makes modeling and clinical validation of findings
challenging.
The advent of high throughput next generation sequencing has
enabled rapid sequencing of the entire human genome. Recent
advances have seen this technology applied to RNA. Tissue RNA
transcription profiles can now be quantified and mapped to their
precise locations on the genome. This is a valuable new tool in
exploratory studies to identify disease mechanisms, as it is possible to
achieve a ‘snapshot’ of the RNA output of a specific tissue. By
identifying and quantifying RNA production in muscle biopsies, it is
possible to identify genes that are differentially expressed between
samples, as well as identifying non-coding RNA, pseudo- and novel
genes. This enables identification of altered cellular pathways between
IIM, IBM and controls and highlights targets for future investigation.
Methods: RNA was extracted from muscle biopsies using commer-
cially available kits (QIAshredder and Qiagen RNeasy columns) and
pooled into 3 samples (IM, IBM and control) for next generation
sequencing. RNA was extracted from 5 muscle biopsies for each of
the IIM and control group, and 2 for the IBM group. The muscle
transcriptome was determined using next generation sequencing
(Illumina Hi-Seq 2000, Poly Aþ extraction). Data were mapped onto
the human genome and changes in expression were analysed.
Results: Differences were noted between Jo-1, IBM and control
pooled samples for a wide range of both coding and non-coding RNA.
MHC 1 and 2 were upregulated in Jo-1 myositis and IBM. B2-
microglobulin (a subunit of MHC class 1) was strongly expressed in
RNA extracted from Jo-1 myositis (12.39 fold increase vs control) and
IBM (5.25 fold change vs control) muscle biopsies. CD74 was
upregulated in Jo-1 myositis and IBM (9.59 and 6.34 fold increase
respectively).
Conclusions: Results suggest that MHC 1 and 2 play a role in the
pathophysiology of both Jo-1 myositis and IBM. MHC 1 and 2 are
most highly expressed in Jo-1 myositis, but also upregulated in IBM.
This suggests possible defective antigen presentation and a muscle
driven autoimmune process in these conditions. Sample size is limited,
and sequencing data were obtained from pooled samples. However,
this study demonstrates the feasibility of a next generation sequencing
approach to evaluate RNA transcription in two complex and poorly
understood conditions.
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O44. THE DEVELOPMENT OF PERIPHERAL JOINT
EROSIONS AND RADIOGRAPHIC SACROILIITIS HAS
STRIKING ASSOCIATION WITH CERTAIN HLA ALLELES AND
HAPLOTYPES: GENOTYPE–PHENOTYPE CORRELATION OF
283 CONSECUTIVE PSORIATIC ARTHRITIS PATIENTS
Muhammad Haroon1, Jon T. Giles2, Robert Winchester3 and
Oliver FitzGerald1
1Department of Rheumatology, St Vincent’s University Hospital,
Dublin, Ireland, 2Rheumatology, Columbia University, New York,
NY and 3Rheumatology, Columbia University Medical Centre,
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Background: We have previously shown in a rigorously ascertained
PsA cohort the considerable genetic heterogeneity, which provided
preliminary evidence that MHC genes determine quantitative traits
within the PsA phenotype with different patterns of MHC effect. We
now extend these findings by performing detailed clinical phenotyping
of PsA cases to better characterize the clinical features associated
with particular HLA class I alleles and their haplotypes.
Methods: A consecutive cohort of 283 PsA patients who were
previously enrolled in a genetics study was included, and patients
were invited to attend a dedicated research clinic. Following informed
consent, patients underwent a detailed skin and rheumatologic
assessment including disease activity measures (PASI, Body Surface
Area (BSA) for Psoriasis (Ps); DAS28 CRP, HAQ for PsA) and
radiographs were taken for involved joints along with hands, feet
and sacroiliac joints. In addition, an extensive medical record review
was performed to obtain information regarding their previous psoriatic
disease features.
Results: A total of 283 PsA patients [mean age 54.612 years; 52%
female; mean PsA duration¼ 199 years; 25% with sacroiliitis; 43.5%
with radiographic peripheral joint erosions; median current PASI¼ 2.1]
were studied. In univariate analysis, the inheritance of B*27:05 was
associated with a more severe joint disease phenotype, and the
presence of HLA-C*06, on any haplotype, conferred a reciprocal
phenotype of significant negative associations with arthritis severity.
B*08 and B*08–C*07 (EH8.1) were correlated with a more severe but
delayed arthritic phenotype. The predictive value of these haplotypes
was confirmed by logistic regression, which after adjustment for
confounders showed, for example, the probability of developing
sacroiliitis was almost completely determined by the inheritance of
EH27.1, EH8.1 or C*05 (adjusted for age, PsA duration, uveitis, and
maximal PASI score). Similarly, the probability of developing peripheral
joint erosions was strongly associated with the presence of EH27.1,
EH8.1 or C*03, figure B (adjusted for gender, PsA duration and lumbar
axial disease).
Conclusions: Certain HLA alleles, and, most strikingly particular
haplotypes, contribute importantly to the magnitude of traits compris-
ing the diverse phenotypes of PsA, but this contribution does not
completely parallel the role of these alleles or haplotypes in
determining susceptibility.
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O45. ANKYLOSING SPONDYLITIS IS STRONGLY
ASSOCIATED WITH VARIANTS IN THE CMG2 GENE
Tugce Karaderi1, Carla J. Cohen1, Sarah Keidel1, Louise
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and B. Paul Wordsworth1,5
1Botnar Research Centre, Nuffield Department of Orthopaedics,
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Oxford, 2Epidemiology Group, Institute of Applied Health Sciences,
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School of Social and Community Medicine, University of Bristol,
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Background: AS is a polygenic inflammatory disease with well-
established contributions from the genes HLA-B*27, ERAP1 and
IL23R. Whole genome association studies (GWAS) have identified
more than 11 additional loci associated with AS, some of which have
been independently confirmed, such as KIF21B, loci at 2p15 and
21q22. Other loci, such as CARD9, TNFRSF1A and RUNX3 are
strongly implicated, and are subject to confirmation and fine mapping
in ongoing studies using the ImmunoChip. Single nucleotide poly-
morphisms (SNPs) in the CMG2 gene, also known as ANTXR2, have
shown suggestive association with AS in two previous GWAS.
However, SNPs in CMG2 were not included on the ImmunoChip. We
have undertaken an independent replication of the TASC and
WTCCC2 SNPs (either genotyped or imputed) in CMG2 that showed
suggestive association with AS previously (P<2 x 10–5).
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Methods: We studied 2978 new AS cases from the UK, and
genotyped them for one coding SNP and eight non-coding SNPs in
CMG2 by KASPar technology (KBioscience, Hoddesdon Herts). We
compared the allele frequencies in these cases to unrelated healthy
individuals from the Avon Longitudinal Study of Parents and Children
(ALSPAC) study (n¼8365) using contingency tables.
Results: Control data were available for eight of the nine SNPs, but not
for the single coding SNP in the ALSPAC data set. A second ALSPAC
SNP was not well imputed and was therefore excluded from the study.
Of the non-coding SNPs, one showed genome-wide significant
association (SNP1 P¼1.2 x 10–22, odds ratio¼0.72, 95% CI 0.68,
0.77). The next two most strongly associated markers were SNP2
(P¼0.0001) and SNP3 (P¼ 0.0005); one further SNP was associated
(P¼0.01) and three were not.
Conclusions: We have replicated and extended the suggestive
association of CMG2 with AS. Its role in AS is not immediately
obvious. CMG2 encodes capillary morphogenic protein 2, which is
dramatically up-regulated in vitro when cultured human umbilical
venous endothelial cells are induced to undergo capillary morphogen-
esis. Its interactions with collagen IV and laminin are also consistent
with this role. In mice, CMG2 is expressed on the vasculature in vivo
and is an angiogenic regulator. A hallmark of inflammation is increased
vascular permeability, one potential consequence of which is
angiogenesis. However, nothing is known about the role of CMG2 in
the context of angiogenesis and inflammation. Subchondral vascular-
ization in the femoral head has been described in AS at the time of hip
joint replacement, and a significant increase in microvessels has been
documented in bone marrow adjacent to the zygapophyseal joints in
AS patients; both these processes may suggest a role for CMG2 in this
disease.
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O46. ESTIMATING HERITABILITY OF RESPONSE TO
TREATMENT WITH ANTI-TNF BIOLOGIC AGENTS USING
LINEAR MIXED MODELS
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Background: The effectiveness of treatment with TNF inhibitors in RA
is variable. A proportion of the variance may be underpinned by
genetics; however studies, to date, have failed to identify robust
genetic markers of response. Potential reasons include (i) there is little
genetic basis to treatment response (ii) lack of statistical power of the
studies undertaken or (iii) lack of an appropriate measure of response
i.e. the 28-joint count DAS (DAS28). The aim of this study was to
estimate heritability of treatment response using genome-wide genetic
variation data in a large cohort of TNF-treated RA patients from the
UK; and to investigate heritability of the individual components of the
DAS28.
Methods: 1,168 RA patients, recruited into the BRAGGSS cohort
were genotyped using Affymetrix or Illumina genome-wide single-
nucleotide-polymorphism (SNP) arrays. Array datasets were merged
following imputation and quality control (QC). Genome-wide Complex
Trait Analysis (GCTA) software was used to estimate heritability.
Related individuals were removed from the genetic relationship
matrix (GRM). The DAS28 was calculated at treatment initiation
and at 6 months following treatment. Outcome included change in:
DAS28, swollen joint count, tender joint count (TJC), ESR, and patient
VAS.
Results: Following QC, 3,140,396 SNPs were available for analysis in
1,140 patients. The cohort was 78% female, 78% were concurrently
treated with DMARDs and the mean DAS28 at inclusion was 6.5. The
GRM explained 24% of the variance in treatment response when
DAS28 was investigated. The variance explained by the GRM was
lowest for TJC (5%) and highest for ESR (34%).
Conclusions: The amount of variability in treatment response
explained by genetic variation was modest. The lack of consistent
genetic signal for this phenotype is likely to be further compounded by
the use of a composite measure i.e. DAS28. Future, well powered
genetic association studies should prioritize objective components of
DAS28 i.e. ESR.
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O47. MUSCULOSKELETAL PAIN IS ASSOCIATED WITH BMI
THROUGH SHARED GENETIC FACTORS
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Background: Chronic musculoskeletal pain is a common condition in
Western societies with prevalence of 5–15%. It is poorly understood
and inadequately managed. It is known to be influenced by genetic
factors but to date few genetic variants have been reliably confirmed.
There is, however, a well documented positive association between
chronic pain and elevated BMI, with people having raised BMI being
more likely to manifest chronic pain. Longitudinal studies suggest that
BMI does not arise as a result of pain limiting activity or exercise.
Rather, it exists prior to the onset of pain, and thus can be considered
a true risk factor for developing chronic pain. A number of studies have
shown musculoskeletal pain to have genetic component [1,2] but to
date few variants have been successfully and convincingly demon-
strated identified. In contrast to our knowledge of the genetics of pain,
however, BMI has been one of the success stories of the genome-wide
association study (GWAS) era, with over 50 genetic regions identified
as associated with BMI [3]. We asked the question: do pain and BMI
share genetic factors, as a route to identifying genetic variants
associated with CWP.
Methods: We used a classical twin design to determine the nature of
the mechanism underlying this relationship. A large population-based
sample of female twins was studied (TwinsUK), having information on
subacute pain (SP). This was defined by having pain on both left and
right sides of the body, above and below the diaphragm, lasting 7 days
or longer and was ascertained by validated questionnaire (London
Fibromyalgia Epidemiology Study Screening Questionnaire). BMI had
been measured during a clinical visit. Bivariate modeling was
performed to determine the relative contribution of genetic and
environmental factors to the two phenotypes.
Results: The female twins (n¼ 2588) had a prevalence of SP of 23%, a
mean age of 59.2 years and a mean BMI of 25.2 kg/m2. Heritability
estimates for SP¼49.9% (95% CI 42.8%, 57.4%) and BMI¼ 77.8%
(95% CI 71.5%, 84.1%). Bivariate modeling showed that a major part
(80%) of the phenotypic correlation between SP and BMI was
accounted for by shared genetic factors (P¼2.7 x 10–7).
Conclusions: Our findings of shared genetic factors underlying the
two phenotypes suggest that research into the aetio-pathology of SP
might fruitfully be directed towards genetic variants associated with
BMI.
Disclosures: The authors have declared no conflicts of interest.
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O48. GENES CONTRIBUTING TO PAIN SENSITIVITY IN THE
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Background: Sensitivity to pain varies considerably between indivi-
duals and is known to be heritable. Increased sensitivity to experi-
mental pain is a risk factor for developing chronic widespread pain—a
common (prevalence¼9%) and debilitating symptom. To understand
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better mechanisms underlying pain sensitivity and to search for rare
gene variants (minor allele frequency<5%) influencing pain sensitivity
we explored the genetic variation in individuals’ response to experi-
mental pain.
Methods: Quantitative sensory testing (QST) to heat pain was
performed in 2500 volunteers from the TwinsUK register (TUK):
exome sequencing to a depth of 70X was carried out on singletons
selected from the high/low ends of the sensitivity distribution, in 2
subsamples (n¼200 each, 100 at each extreme, total n¼ 400). We
compared 6 different classes of rare variant analysis method, and
performed pathway analysis to understand better the links between
genetic variants observed. We input 138 unique genes harbouring a
rare variant (with P<0.01) into causal reasoning which uses directed
molecular interactions to work upstream from the genes to identify
regulators that have a causally correct regulatory role. Correctness is
determined by giving each input gene a direction of effect and here we
assumed loss of function.
Results: The pattern of rare variation distribution was different in the
pain insensitive and pain sensitive groups, with the insensitive
individuals having greater numbers of rare variants. Rare variant
analysis methods were highly correlated. GZMM was the gene most
highly associated with pain sensitivity (P¼6.86 x 10–5 not statistically
significant after correction for multiple testing). Network analysis of the
138 most associated genes revealed the angiotensin II regulatory
network to be significantly associated with pain sensitivity (Bonferroni
corrected P¼ 3.8 x 10–4). Angiotensin II had direct causal connections
to 12 of the genes from our 138, which increased to 30 if one
intermediary node was allowed in the network.
Conclusions: Data from animal and small clinical studies support a
role for the angiotensin pathway in pain. A recent phase II study
reported that a novel AT2 receptor antagonist successfully reduced
post-herpetic neuralgia (http://www.spinifexpharma.com.au/DRUG-
DISCOVERY.html). The present study did not, as we had hoped,
identify novel variants having large effect on pain. However, we did
observe a difference in rare variant distributions between the pain
sensitive and insensitive groups. Furthermore, our work adds weight to
evidence that the angiotensin II pathway plays an important role in pain
sensation in humans and the components of the pathway may be
targeted to create novel analgesics.
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O49. THE ROLE OF PROTEIN KINASE D SIGNALLING IN THE
INDUCTION OF MATRIX METALLOPROTEINASES IN HUMAN
ARTICULAR CHONDROCYTES
Jonathan Baker1, Gary J. Litherland1 and Andrew D. Rowan1
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Background: The destruction of articular cartilage is a central feature
of arthritis. The activity of collagenase enzymes, induced by pro-
inflammatory cytokines, is a key step in this process and thus an
important therapeutic target. The aim of the present study is to
elucidate the signalling processes that regulate collagenase expres-
sion, focusing on the role of the small family of serine/threonine
kinases termed protein kinase D (PKD). PKD consists of 3 distinct
isoforms, all of which are expressed in articular chondrocytes.
Methods: Human primary articular chondrocytes were isolated by
enzymatic digestion of OA cartilage and grown in monolayer culture.
Chondrocytes were pre-incubated with the PKD inhibitor kb-NB142-
70 and other agents, and then stimulated with the pro-inflammatory
cytokine combination IL-1 and oncostatin M (OSM). Chondrocytes
were also subject to siRNA-mediated gene silencing in some
experiments. Lentiviral expressed shRNA mediated gene silencing
was also used. Overexpression of PKD1 was performed in the human
chondrosarcoma cell line SW1353. Western blotting was used to
assess effects of gene silencing upon key signalling pathways.
Alteration in gene expression was assessed using real time PCR.
Results: Stimulation of chondrocytes with either IL-1 or OSM lead to an
increase in protein levels of each PKD isoform as well as increases in
phosphorylation. PKD phosphorylation was dependent on Protein
Kinase C (PKC) activity. Inhibition of PKD activity lead to a decrease in
collagenase expression. Silencing of PKD3 in chondrocytes stimulated
with IL-1 in combination with OSM lead to the inhibition of collagenase
gene expression, whilst PKD2 silencing had no effect. Overexpression of
PKD1 caused decreased collagenase gene expression in SW1353.
PKD3 activity regulated the phosphorylation of STAT1 and STAT3, with a
loss of serine and tyrosine phosphorylation upon PKD3 gene silencing.
Conclusions: Here we describe how closely related PKD isoforms
regulate the expression of collagenase genes in a different manner.
Silencing of PKD3 down regulated collagenase expression, with the
same effect being observed upon overexpression of PKD1. This
suggests the two isoforms may have opposing functions within
chondrocytes. This regulation of collagenase expression is shown to
be dependent on STAT serine and tyrosine phosphorylation.
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O50. EFFECTS OF PTPN22 R620W ON NEUTROPHIL
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Background: A single nucleotide polymorphism (SNP) variant of the
PTPN22 gene, known as PTPN22 R620W, is a significant risk factor for
the development of RA and other autoimmune inflammatory diseases
such as vasculitis. PTPN22 encodes a protein tyrosine phosphatase
Lyp, which is expressed in all leucocytes. Most studies of Lyp function
have focused on lymphocytes and yet Lyp is expressed at the highest
levels in neutrophils. These cells are thought to be important in the
pathogenesis of RA, where they are found in abundance in the affected
synovial joints and play an important role in organ damage in small
vessel vasculitis. However, the role of Lyp and the effects of PTPN22
R620W expression have not been studied in neutrophils. Here we have
investigated neutrophil function in healthy control subjects and
vasculitis patients, control (GG), heterozygote (AG) and homozygote
(AA) for the R620W allele.
Methods: 62 healthy individuals were genotyped for the PTPN22
R620W variant. Neutrophils were isolated from peripheral blood of age
and sex matched control (GG) and variant (AG) expressing individuals.
Cells were also isolated from GG and AA expressing vasculitis
patients. Calcium signalling was assessed after stimulation of Indo-1
AM dye-loaded cells. Reactive oxygen species (ROS) production was
measured using DHR oxidation as assessed by flow cytometry.
Results: The R620W allele (A) was highly expressed in healthy controls
(AG¼28%, AA¼1%, GG¼71%), and 17 heterozygous/variant
individuals were identified. An enhanced calcium flux in response to
stimulation with fMLP was observed in AG neutrophils compared with
GG neutrophils (GG¼ 0.210.027 (indo FL ratio), AG¼0.240.035,
n¼ 4). This was also observed in neutrophils from vasculitis patients
homozygous for the R620W allele (AA¼0.28 0.02, n¼2). Baseline
production of ROS was similar in unstimulated GG and AG neutrophils
(GG¼93 8 MFI, AG¼8023 MFI, n¼3). In cells stimulated with
fMLP or primed with TNFa, ROS production increased in neutrophils
from GG individuals but the increase in AG neutrophils was much less.
However, when neutrophils were first primed with TNFa then
stimulated with fMLP, ROS production was greatly enhanced in AG
neutrophils in comparison with control GG cells (GG¼ 21566 MFI,
AG¼ 392162, MFI n¼ 3).
Conclusions: The function of Lyp in neutrophils has not previously
been investigated, and our studies suggest that Lyp is an important
regulator of neutrophil activation and function, particularly following
priming with TNFa. The allelic variant of PTPN22 may confer
advantages in the individuals expressing it, by enhancing the ability
of neutrophils to kill bacteria through increased ROS production.
However, these hyperactive cells may have detrimental effects on
chronic diseases such as RA and ANCA vasculitis, which are both
associated with PTPN22 R620W expression and where neutrophils are
important mediators of disease pathogenesis.
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O51. MACROPHAGE METABOTYPES IN THE HYPOXIC
INFLAMMATORY ENVIRONMENT ASSESSED USING
METABOLOMIC PROFILING
Martin A. Fitzpatrick1 and Stephen P. Young1
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Birmingham, Birmingham, UK
Background: Macrophages are abundant in the synovium of RA and
are the major source of many inflammatory cytokines, including TNFa.
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Disease severity correlates strongly with both synovial macrophage
abundance and activation status but inversely with oxygen levels.
Given the importance of oxygen to cell metabolism, differentiation and
function, we hypothesized that the unique metabolic and oxygen
environment of the joint may drive the differentiation of aggressive
macrophages.
Methods: Human monocytes were differentiated into macrophage
subsets (M1 and M2c) under GM-CSF and M-CSF polarizing
conditions and under a variety of oxygen conditions, and stimulated
with lipopolysaccharide (LPS). Cell metabolites were extracted for
metabolomic analysis using NMR spectroscopy and secreted cyto-
kines assessed. NMR spectra were analysed using partial least
squares discriminant analysis (PLS-DA) to build models describing
differences in metabolites, and partial least squares regression (PLS-
R) to correlate these to cytokine production. Metabolites differentiating
between experimental groups and pathways were identified and
analysed using bespoke metabolic analysis tools.
Results: Macrophage subtypes exhibited unique metabolic patterns
that, while shifting during differentiation, remained distinct throughout
stimulation and subsequent activation with LPS. Differentiation of
monocytes to both M1 and M2c macrophages increased production of
myo-inositol, a marker of calcium signaling, and the proteinogenic
amino acid serine. These correlated strongly with LPS-induced IL-6
production. M2c macrophages showed increased arginine production
which correlated with IL-10 production, a key M2c anti-inflammatory
cytokine. M1 macrophages exhibited higher glycolytic flux and a
reduction in citric acid cycle metabolites.
Differentiation under hypoxia gave an altered metabolic phenotype,
with a reduced citric acid cycle, and increased glycolytic flux.
However, both M1 and M2c subsets remained metabolically distinct.
Strikingly, differentiation of both M1 and M2c macrophages under
reperfusion conditions resulted in an activated metabolic profile,
indistinguishable from that induced by LPS, but interestingly up-
regulation of IL-6 was not seen.
Conclusions: Classically-activated M1 macrophages and regulatory
M2c macrophages each possess a unique metabotype that, while
altered by environmental stressors, remains unique to the cell. This
stability may depend on tight regulation at the gene and protein level,
and we suggest that this is closely coupled to the macrophage
differentiation programme. The increased arginine in M2c, for
example, suggests a down-regulation of the arginase pathway in this
resolution-associated subset. Therefore, while a capacity to adapt to
the environment clearly remains, differentiation constrains this. We
propose that this may impair subset survival or function in abnormal
environments such as the rheumatoid synovium.
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O52. SYNOVIAL FIBROBLASTS SHAPE THE RECRUITMENT
AND MIGRATION PATTERNS OF LYMPHOCYTES DURING
RESOLVING AND PERSISTENT ARTHRITIS
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Background: Fibroblasts actively regulate the recruitment of leucocytes
by endothelial cells, acting in a pro- or anti-inflammatory manner
depending on their site of origin. The phenotype of the fibroblast may be
a critical determinant of whether leucocyte recruitment, and therefore
inflammation, resolves or persists. Here we examined how synovial
fibroblasts from different stages of arthritis influenced the recruitment of
peripheral blood lymphocytes (PBL) and their onward migration.
Methods: Fibroblasts were isolated from DMARD naive patients in the
Birmingham Early Arthritis Cohort with resolving (12week symptom
duration) or persistent arthritis. Rheumatoid arthritis (RA) cohorts were
categorized based on the stage of the disease at the time of sample
collection: very early (12week duration); newly presented established
(>12week duration) or long established treated RA undergoing
replacement surgery. Two forms of co-cultures were developed,
appropriate to answer specific questions: (i) To assess the effects on
recruitment, endothelial cells and fibroblasts were cultured on
opposite sides of porous filters and incorporated into a novel flow
chamber. PBL were perfused and observed as they bind to the
endothelial surface. (ii) To examine effects on migration, endothelial
monolayers were formed on a filter above a collagen gel in which
fibroblasts were incorporated. PBL migration through the construct
and their location within the gel were assessed. Conditioned media
from co-cultures were collected and analysed by Luminex.
Results: In initial data, fibroblasts from patients with persistent
inflammation increased the ability of endothelial cells to support PBL
recruitment from flow in a disease duration-specific manner, with
binding increasing from very early <established <replacement. Similar
levels of binding were observed on co-cultures incorporating fibro-
blasts from patients with resolving inflammation and very early RA. In
the multi-cellular gel model, all fibroblasts promoted PBL transen-
dothelial migration but had no effect on the number of PBL entering
into the gel. Interesting, a greater proportion of PBL migrated into the
lower half of the gel when fibroblasts from patients with very early and
established RA were incorporated. Elevated levels of IL-6, IL-1b, IL-8,
Groa and IP-10 were detected in the supernatants from RA co-cultures
compared with resolving co-cultures. The presence of resolving
fibroblasts dramatically reduced the secretion of these cytokines and
chemokines by endothelial mono-cultures, suggesting they have a
suppressive effect.
Conclusions: Collectively these preliminary data indicate that
changes in the ability of fibroblasts to influence endothelial and
lymphocyte behaviours may occur very early in the development of
RA, possibly before clinical criteria are fulfilled. Moreover, some of
these changes are distinct from the phenotype exhibited by fibroblasts
taken from acutely resolving arthritis.
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O53. BIOLOGICAL ROLES OF C5ORF30 IN RHEUMATOID
ARTHRITIS
Munitta Muthana1, Holly Davies1, Sachin Khetan1,
Gbadebo Adeleke1, Sarah Hawtree1, Simon Tazzyman2,
Fiona Morrow1, Barbara Ciani3 and Gerry Wilson1
1Infection and Immunity, University of Sheffield, Sheffield,
2Oncology, University of Sheffield, Sheffield and
3Chemistry, University of Sheffield, Sheffield, UK
Background: A recent genome wide association study identified the
variant rs26232 in the first exon of an uncharacterized gene C5orf30. In
addition, this variant is also associated with severity of radiological
joint damage suggesting a role in tissue breakdown. To date there is
no function assigned for C5orf30 and neither the gene or protein
coded show homology to any known functional sequences. However,
C5orf30 is highly conserved in chimpanzee, dog, cow, mouse,
chicken, and zebrafish (orthologs). The aim of this study is to
determine the biological roles of C5orf30 in health and RA.
Methods: Real time PCR and western blotting was used to determine
C5orf30 transcript and protein levels in fibroblast-like synovial cells (FLS-
stimulated with TNF and hypoxia) and peripheral blood leucocytes
isolated from RA patients and healthy individuals. Immunohistochemistry
using synovial samples was used to determine cellular expression using
anti-C5orf30 and antibodies to macrophages (CD68), fibroblasts (5B5), T
(CD3) and B (CD19) cells. To investigate gene function siRNA was used
to knockdown C5orf30 in synovial FLS in vitro and we have used
morpholino antisense oligonucleotide (MO)-mediated knocked down of
C5orf30 in zebrafish embryos (fms:mcherry) in vivo.
Results: Expression of C5orf30 was detected at lower levels in
peripheral blood leucocytes of RA patients compared with healthy
controls (117 patients vs 102 controls, P¼0.00052). C5orf30 was
expressed in joint FLS and was found to be up regulated following
treatment with hypoxia (8-fold) and down-regulated by TNF-a
(0.5-fold). Confocal microscopy revealed C5orf30 was strongly
expressed in both the nuclear and cytoplasmic compartment of
synovial lining cells including macrophages and fibroblasts but not B
and T cells. C5orf30 was undetectable in arthroscopy sections
obtained from OA or control (knee replacement) patients. So far,
80% C5orf30 knockdown has been achieved in FLS and this led to
increased invasion into matrigel. Interestingly, MO-mediated knock-
down of C5orf30 impeded zebrafish development and increased total
macrophage numbers by 40% following tail-fin injury compared with
knockdown of a non-targeting control MO.
Conclusions: C5orf30 is expressed at both the transcript and protein
level in synovial cells but not in circulating PBMC obtained from RA
patients, suggesting that C5orf30 is expressed in a tissue-specific
manner. C5orf30 knockdown increased FLS migration into matrigel
suggesting C5orf30 is negatively regulating cellular invasion. In
addition knockdown of C5orf30 in a zebrafish model of inflammation
increased total macrophages numbers at the site of injury, indicative of
a role for C5orf30 in macrophage development. We are currently
performing proteomic studies including NMR and mass spectrometry
to work out the biology of this important marker in the pathogenesis
and severity of RA.
Disclosures: The authors have declared no conflicts of interest.
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O54. AUTOCITRULLINATED PORPHYROMONAS
GINGIVALIS PEPTIDYLARGININE DEIMINASE: A NOVEL
ANTIGEN WITH POTENTIAL FOR BREACHING IMMUNOLOGIC
TOLERANCE IN RHEUMATOID ARTHRITIS
Anne-Marie Quirke1, Elena Lugli1, Natalia Wegner2, Peter Charles1,
Bart Hamilton3, Muslima Chowdhury1, Jimmy Ytterberg4,
Jan Potempa5, Benjamin Fisher2, Geoffrey Thiele3, Ted Mikuls3 and
Patrick Venables1
1Kennedy Institute of Rheumatology, University of Oxford, Oxford,
2Kennedy Institute of Rheumatology, Imperial College London,
London, UK, 3University of Nebraska Medical Centre, University of
Nebraska, Omaha, NE, USA, 4Department of Medicine, Karolinska
Institute, Stockholm, Sweden and 5Department of Microbiology,
Jagiellonian University, Krakow, Poland
Background: Rheumatoid arthritis (RA) is characterized by auto-
immunity to citrullinated proteins. There is increasing molecular and
epidemiological evidence linking periodontitis (PD) to RA.
Porphyromonas gingivalis is unique amongst periodontal pathogens
in possessing a citrullinating enzyme, peptidylarginine deiminase
(PPAD) with the potential to generate citrullinated antigens driving
the autoimmune response in RA. Because of the potential importance
of PPAD in RA pathogenesis, we have examined the immune response
to PPAD in a cohort of patients with RA compared with normal
controls, in addition to individuals with periodontitis as a positive
control for active P. gingivalis infection.
Methods: PPAD and an inactive PPAD mutant (C351A) were cloned
and expressed and the enzyme activity of both was measured using a
colorimetric PAD assay. Autocitrullination of PPAD was tested by
immunoblotting with the anti-modified citrulline (AMC) antibody and by
mass spectrometry using MASCOT. Enzyme-linked Immunosorbant
assays (ELISAs) using PPAD and C351A were used to test serum from
normal controls (n¼ 80), PD (n¼44) and RA (n¼82), calculated as
units per ml (AU/ml) using a standard curve. Thirteen synthetic
citrullinated peptides spanning the PPAD sequence were synthesized
to test antibody reactivity with specific epitopes. The Mann–Whitney
U-test was used to calculate p-values for differences between the sera
groups for each antigen.
Results: Immunoblotting by AMC showed that PPAD was autocitrulli-
nated with 7 out of a possible 18 citrulline residues demonstrated by
mass spectrometry. Antibodies to PPAD were significantly higher in
the RA sera (median 122 AU/ml), than the PD sera (median 60 AU/ml;
P<0.01) and the healthy control sera (median 70 AU/ml P<0.05).
There was no elevated antibody response in the RA sera to PPAD
when the C351A PPAD mutant was used on ELISA. The specificity of
the anti-citrullinated PPAD response was confirmed by the reaction of
RA sera with multiple epitopes tested with synthetic citrullinated
peptides spanning the PPAD molecule.
Conclusions: The heightened immune response of autocitrullinated
PPAD in RA sera could be part of a cross-reactive anti-citrullinated
protein antibodies (ACPA) response, but more importantly, it could
also indicate that PPAD itself could be a mechanism for breaching
immunological tolerance to citrullinated antigens.
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O55. APREMILAST, AN ORAL PHOSPHODIESTERASE 4
INHIBITOR, IN PATIENTS WITH PSORIATIC ARTHRITIS:
RESULTS OF A PHASE III RANDOMIZED CONTROLLED TRIAL
Adewale O. Adebajo1, Arthur Kavanaugh2, Philip Mease3,
Juan J. Gomez-Reino4, Jurgen Wollenhaupt5, ChiaChi Hu6 and
Randall Stevens6
1Rheumatology, University of Sheffield, Sheffield, UK,
2Rheumatology, University of California San Diego, San Diego, CA,
3Rheumatology, Swedish Medical Centre and University of
Washington School of Medicine, Seattle, WA, USA, 4Rheumatology,
Hospital Clinico Universitario, Santiago, Spain, 5Rheumatology,
Scho¨n Klinik Hamburg Eilbek, Hamburg, Germany and
6Research and Development, Celgene Corporation, Warren, NJ, USA
Background: Apremilast (APR), an oral phosphodiesterase 4 inhibitor,
works intracellularly to modulate pro- and anti-inflammatory media-
tors. PALACE 1 compared APR efficacy and safety vs placebo (PBO) in
patients with active PsA despite prior DMARDs and biologics.
Methods: Patients were randomized 1:1:1 to PBO, APR 20 mg BID, or
APR 30 mg BID stratified by baseline (BL) DMARD use. At week 16,
patients with< 20% reduction in swollen and tender joint counts were
re-randomized to APR 20 mg BID or 30 mg BID (PBO group) or
remained on initial dose (APR groups). All patients continued treatment
through week 24. Stable concurrent DMARD therapy was allowed
(MTX, SSZ, LEF, or combination). Analysis done on per-protocol
population used LOCF methodology for missing data.
Results: 504 patients were randomized and comparable across
treatment arms for demographics, disease characteristics, and prior/
concurrent therapy; 23.6% had prior biologic exposure; 9.3% were
biologic failures. At BL, 64.9% were taking DMARDs (54.2% MTX). At
week 16, more patients receiving APR 20 mg BID (31.3%; P¼ .0140)
and 30 mg BID (41.0%; P< .0001) achieved an ACR20 vs PBO
(19.4%). With APR 30 mg BID, higher ACR20 responses were seen in
the APR monotherapy and biologic-naı¨ve groups vs the overall
population. At week 24, significant improvements in secondary
endpoints were seen with APR vs PBO, including physical function
and pain. APR was generally well tolerated. Adverse events (AEs)
occurring in 5% of any group were diarrhea (PBO 2.4%, 20 mg BID
11.3%, 30 mg BID 19.0%), nausea (6.5%, 9.5%, 18.5%), headache
(4.8%, 10.1%, 10.7%), and URTI (3.6%, 6.0%, 4.2%). Most (>95%)
AEs were mild/moderate; discontinuations due to AEs were similar
across all treatment arms (5–7%). Serious AEs occurred in 7 (PBO), 8
(20 mg BID), and 9 (30 mg BID) patients. There was no greater risk of
opportunistic infections, lymphoma, or cardiovascular events. No TB
reactivation was reported.
Conclusions: APR significantly improved signs and symptoms of PsA
and resulted in statistically and clinically meaningful improvements in
physical function. APR was generally well tolerated with no new safety/
laboratory signals detected.
Disclosures: J.G., Roche, Schering-Plough—Research Grants,
Lecture Fees, Advisory Boards, BMS—Lecture Fees, Advisory
Boards, Wyeth—Lecture Fees, Pfizer, UCB SA—Advisory Boards.
C.H., Celgene Corporation—Employee. A.K., Abbott, Amgen,
AstraZeneca, BMS, Celgene, Centocor-Janssen, Pfizer, Roche,
UCB—Research Grants. P.M., Abbott, Amgen, BiogenIdec, BMS,
Genentech Janssen, Lilly, Pfizer, UCB—Research Grants, Consultant
Fees, Speaker’s Bureau, Celgene, Novartis, Roche—Research Grants,
Consultant Fees. R.S., Celgene Corporation—Employee. J.W., Abbott
Laboratories, BMS, MSD, Pfizer, UCB—Consulting Fees. All other
authors have declared no conflicts of interest.
O56. SUSTAINED EFFICACY OF ADALIMUMAB IN PATIENTS
WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS
WITH POSITIVE MRI OF THE SACROILIAC JOINTS OR SPINE
OR ELEVATED C-REACTIVE PROTEIN AT BASELINE
Joachim Sieper1, Desiree van der Heijde2, Maxime Dougados3,
Filip Van den Bosch4, Philippe Goupille5, Suchitrita S. Rathmann6
and Aileen L. Pangan7
1Department of Medicine/Rheumatology, Charite´
Universita¨tesmedizin Berlin, Berlin, Germany, 2Department of
Rheumatology, Leiden University Medical Centre, Leiden,
Netherlands, 3Department of Rheumatology, Hospital Cochin, Paris,
France, 4Department of Rheumatology, Ghent University Hospital,
Ghent, Belgium, 5Department of Rheumatology, CHRU de Tours,
Hoˆpital Trousseau, Tours, France, 6Data and Statistical Sciences,
AbbVie, North Chicago, IL and 7Immunology Development,
AbbVie, North Chicago, IL, USA
Background: Adalimumab (ADA) is currently approved in the EU for
the treatment of adults with severe axial SpA without radiographic
evidence of AS, but with objective signs of inflammation by elevated
CRP and/or MRI who have had an inadequate response to, or are
intolerant to non-steroidal anti-inflammatory drugs.
Methods: ABILITY-1 is an ongoing double-blind (DB), randomized,
controlled trial in non-radiographic axial SpA (nr-axSpA) patients
fulfilling ASAS axial SpA criteria but not modified New York criteria who
had an inadequate response, intolerance, or contraindication to
NSAIDs. ADA 40 mg every other week or placebo (PBO) was given
for a 12-week DB period followed by open-label ADA for up to 144
weeks. This post-hoc analysis describes the long-term efficacy and
safety of ADA in patients with nr-axSpA who had a positive baseline
(BL) MRI (defined as a SPARCC score 2 for either the SI joints or
spine) or an elevated CRP at BL. Clinical responses were summarized
by observed case and non-responder imputation (NRI) analyses.
Results: 142 (69 ADA, 73 PBO) of the total efficacy study population
(N¼185) had a positive MRI at BL or elevated CRP (MRIþ/CRPþ). 139
patients completed the DB period; 111 patients had data available for
week 68 analysis. BL demographics and disease characteristics of the
MRIþ/CRPþ subpopulation were comparable to the total population.
At week 12, efficacy results were comparable between the total
population and the MRIþ/CRPþ subpopulation (Table 1). Efficacy was
sustained with long-term ADA therapy up to week 68. At week 68,
among the MRIþ/CRPþ subpopulation (N¼111), 69% of patients had
an ASAS40 response and 48% were in a state of inactive disease as
TABLE 1. Results
PBO (n¼ 165) APR 20 mg BID (n¼ 163) APR 30 mg BID (n¼ 161)
ACR20 at week 16, % (NRI %) 19.4 (19.4) 31.3* (31.3) 41.0*** (40)
APR alone (n¼ 172), % (NRI %) 10.5 (10.5) 31.5* (31.5) 50.8*** (48)
APRþDMARDs (n¼ 317) 24.1 31.2a 35.0a
ACR20 at week 16 23.7 31.2a 43.3*
Biologic-naı¨ve (n¼ 363)
APR alone (n¼ 89), % (NRI %) 11.5 (11.5) 24.1a (24.1) 58.8* (56)
APRþDMARDs (n¼ 274) 27.2 33.3a 37.2a
Select secondary endpoints at week 24
ACR50, % 4.2 15.3* 19.9***
ACR70, % 0.6 5.5* 11.2***
HAQ-DI, LS mean  (S.E.) –0.077 (0.037) –0.212 (0.037)* –0.260 (0.037)*
SF-36 PF, LS mean  (S.E.) 1.46 (0.671) 3.50 (0.675)* 5.06 (0.674)***
Efficacy analyses conducted using per-protocol population (N¼ 489); last observation carried forward (LOCF) used for missing data. NRI: nonresponder imputation.
*P< 0.05; ***P0.0001; aP¼NS vs PBO.
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measured by the ASDAS, with comparable results observed in the
total study population (N¼ 144) (Table 1). As of week 68, in the total
safety population (ADA exposure¼193.3 patient-years), there were 3
serious infections including 1 case of tuberculosis, 1 death due to
suicide, but no malignancies, demyelinating diseases, or lupus-like
syndromes.
Conclusions: Long-term data demonstrate sustained efficacy with
ADA in nr-axSpA patients who have inadequate response, intolerance
or contraindication to NSAIDs, in both the total efficacy study
population and in a subpopulation with objective evidence of
inflammation by MRI or elevated CRP. Almost half of the patients
remaining in the study at week 68 is in ASDAS inactive disease. Long-
term safety data were consistent with the known safety profile of ADA
in AS and other immune-mediated diseases.
Disclosures: M.D., AbbVie, BMS, Merck, Pfizer, Sanofi-Aventis,
UCB—Research Grants, Consulting Fees. P.G., AbbVie, BMS,
Merck, Pfizer, UCB—Participated at Advisory Boards and Symposia.
A.P., AbbVie—Employee, Stock and/or Stock Options, AbbVie
sponsored the study, contributed to its design, and participated in
the collection, analysis, and interpretation of the data, and in the
writing, reviewing, and approval of the final version. S.R., AbbVie—
Employee, Stocks/Stock Options. J.S., AbbVie, Merck, Pfizer, UCB—
Research Grant, Consulting Fees. F.V., AbbVie, Merck, Pfizer, UCB—
Consulting Fees, Speaker’s Fees. D.V., AbbVie, Amgen, AstraZeneca,
BMS, Centocor, Chugai, Eli Lilly, GSK, Merck, Novartis, Otsuka, Pfizer,
Roche, Sanofi-Aventis, Schering-Plough, UCB, Wyeth—Consulting
fees, Imaging Rheumatology—Director.
O57. SPINAL INFLAMMATION IN THE ABSENCE OF SI JOINT
INFLAMMATION ON MRI IN PATIENTS WITH ACTIVE
NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS
Desiree van der Heijde1, Joachim Sieper2, Walter P. Maksymowych3,
Matthew A. Brown4, Suchitrita Rathmann5 and Aileen L. Pangan6
1Rheumatology, Leiden University Medical Centre, Leiden,
Netherlands, 2Gastroenterology and Rheumatology, Charite´
Universita¨tsmedizin, Berlin, Germany, 3Medicine, University of
Alberta, Edmonton, AB, Canada, 4Autoimmunity Program, University
of Queensland Diamantina Institute, Brisbane, QLD, Australia,
5Data and Statistical Sciences, AbbVie, North Chicago and
6Immunology Development, AbbVie, North Chicago, IL, USA
Background: The imaging arm of the ASAS axial SpA criteria requires
the presence of sacroiliitis on MRI or radiographs. In patients with non-
radiographic axial SpA (nr-axSpA), there may be inflammation along
the spine in the absence of sacroiliac joint (SIJ) inflammation on MRI.
This analysis evaluated the existence of spinal inflammation on MRI at
baseline (BL) in nr-axSpA patients with and without inflammation in the
SIJs on MRI.
Methods: ABILITY-1 is an ongoing multicentre, randomized, con-
trolled trial of adalimumab vs placebo in patients with nr-axSpA
classified using the ASAS axial SpA criteria, who had an inadequate
response, intolerance to, or contraindication for NSAIDs. MRI of the
SIJ and spine performed at BL were centrally scored using the
SPARCC method (6-DVU method for the spine) by 2 independent
readers blinded to the treatment codes. Mean scores of the readers
were used. SPARCC score 2 for either the SIJ or spine was used as
the operational definition of positive MRI evidence of inflammation. For
these analyses, all patients were combined, independent of
randomization.
Results: Mean symptom duration of the study population (N¼185)
was 10 years. At BL, 48% of patients were reported by the local
investigator to have past or present MRI evidence of sacroiliitis as
required by the ASAS axial SpA criteria. Of patients with available BL
SPARCC scores, 40% had a BL SIJ score 2 and 52% had a BL spine
score 2. Of the patients with BL SPARCC SIJ score <2, 49% had
evidence of spinal inflammation (BL SPARCC spine score 2).
Comparison of BL disease characteristics based on BL spine and
SIJ scores <2 vs 2 were generally comparable except for a greater
proportion of males among those with spine and SIJ scores 2, and
younger age and shorter symptom duration among those with spine
and SIJ scores <2. Similar distribution of SPARCC spine scores were
observed regardless of presence or absence of SIJ inflammation on
MRI. The most frequently involved DVUs with bone marrow edema
were in the lower thoracic and lumbar spine.
Conclusions: Assessment by experienced readers shows that spinal
inflammation on MRI may be observed in half of nr-axSpA patients
without SIJ inflammation on MRI. MRI of both sites might be of value
when evaluating patients with nr-axSpA. These data in patients with
long-standing disease need to be confirmed in patients with shorter
disease duration.
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O58. DISEASE BURDEN IS COMPARABLE IN PATIENTS
WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS
AND ANKYLOSING SPONDYLITIS
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Background: Chronic back pain and functional impairment are
disease characteristics common to all patients with axial SpA,
regardless of the presence of radiographic sacroiliitis in AS or its
absence in non-radiographic axial SpA (nr-axSpA). This analysis
compares baseline disease characteristics of patients with nr-axSpA
and AS in registries and randomized clinical trials (RCT) with
adalimumab (ADA).
Methods: Registry data in this analysis include the German SpA
Inception Cohort (GESPIC) that compared patients with AS by
modified New York criteria (divided into >5 years and 5 years) and
nr-axSpA (5 years) meeting modified ESSG criteria and a prospective
cohort of TNF-naı¨ve SpA patients meeting ASAS criteria for axial SpA
(Kiltz). ADA RCT data were derived from the ATLAS study in AS
patients, and the ABILITY-1 and Haibel studies in nr-axSpA patients.
Patients in RCTs were selected based on a pre-specified level of
disease activity and inadequate response to non-steroidal anti-
inflammatory drugs.
Results: Mean age was similar in nr-axSpA and AS patients, ranging
from 36 to 42 years (Table 1). A higher proportion of AS patients had
elevated CRP as compared with nr-axSpA patients and gender
differences were observed, with nr-axSpA patients being predomi-
nantly female and AS patients primarily male. Symptomatic patients
with nr-axSpA and AS often went undiagnosed for years. Similar levels
of disease activity as measured by the BASDAI, pain scores, and pt
and physician global assessments of disease activity were seen
between nr-axSpA and AS patients in registries and RCTs, with levels
TABLE 1. Results
Total study population MRIþ/CRPþ subpopulation
Week 12a (n¼ 185), % Week 68b (n¼ 144), % Week 12a (n¼ 142), % Week 68b (n¼ 111), %
PBO (n¼ 94) ADA (n¼ 91) PBO (n¼73) ADA (n¼ 69)
ASAS40 15 36 67 14 41 69
BASDAI50 15 35 65 14 39 67
ASAS partial remission 5 16 36 5 19 40
ASDAS inactive disease 4 24 47 4 29 48
aNRI. bObserved data.
BSR AND BHPR ORAL PRESENTATION OF ABSTRACTS Thursday 25 April 2013, 14.00–15.30 i53
of disease activity generally higher in RCT patients due to minimum
levels of baseline disease activity required for study eligibility.
Conclusions: Registry and clinical trial data demonstrate that both nr-
axSpA and AS patients have comparable burden of disease. These
findings suggest that all patients with axial SpA can present with
similar debilitating signs and symptoms requiring treatment regardless
of the extent of radiographic damage.
Disclosures: J.A., AbbVie—Employee, Stock and/or Stock Options.
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O59. A PROPOSED ALGORITHM AND ITS PERFORMANCE
EVALUATION FOR THE BEST REFERRAL BY
OPHTHALMOLOGISTS OF ACUTE ANTERIOR UVEITIS
PATIENTS WITH POSSIBLE UNDERLYING
SPONDYLOARTHROPATHY
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Background: Recent reports claim that the prevalence figures of
mostly undiagnosed underlying SpA is more than 60% of patients
presenting with acute anterior uveitis (AAU). Unfortunately, there are
no formal guidelines or referral pathways for AAU patients developed
or endorsed by any international or even national societies. Therefore,
in a condition where significantly delayed diagnosis is common and
where AAU may frequently be the first interaction with medical care, an
opportunity to identify SpA early is often missed leading to less than
ideal care for SpA patients.
Methods: The objectives of our study were: (i) to develop an
assessment algorithm for referral from Ophthalmologists of appro-
priate AAU patients to rheumatology that will aid the early diagnosis of
the SpA; and. (ii) to investigate the prevalence of undiagnosed SpA in
patients presenting with AAU in a primary care ophthalmology setting.
All consecutive patients attending emergency department of local
ophthalmology hospital (RVEEH) with AAU, but who did not have a
known diagnosis of SpA, were eligible to partake in this study. Patients
with any other known cause of AAU were excluded. The HLA-B27
status was checked in all patients, and assessment and onward
referral was made as per a test algorithm which combined clinical
features and HLA-B27. Patients without risk factors for SpA and
who were HLA-B27 negative remained part of the study as a control
group.
Results: 104 consecutive patients attending from September 2011
through to June 2012 were recruited. Mean age of the cohort was
42 15 years, 56.4% were male, HLA- B27 was positive in 52.5%.
After rheumatologic evaluation, 41.5% of patients were noted to have
undiagnosed SpA as per ASAS classification criteria; 64% of them had
radiographic axial SpA, and only 2 patients had peripheral SpA. The
mean age of these newly diagnosed SpA patients was 41 13 years;
average duration of backache was 11.6511 years; and HLA-B27
was negative in only 4 patients. Our algorithm version 1 was noted to
have: sensitivity 100%, specificity 53.5%, PPV 61% and NPV 100%.
Further simple step wise re-analysis of the data revealed that algorithm
version-2 can make following improvements: sensitivity 95%, speci-
ficity 98%, PPV 97.5%, NPV 96.6%, which is undergoing further
testing at present in an additional cohort.
Conclusions: 41.5% of patients presenting with idiopathic AAU have
undiagnosed SpA. Recognition of undiagnosed SpA is an achievable
goal, but requires an integrated multidisciplinary approach. A simple to
apply algorithm is described with excellent sensitivity and specificity
that is currently being validated in an additional cohort.
Disclosures: The authors have declared no conflicts of interest.
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Background: Treatment of PsA has been revolutionized by the use
of anti-tumour necrosis factor inhibitors (TNF). By August 2007,
3 anti-TNFs were approved by The National Institute of Clinical
Excellence (NICE) for the treatment of moderate-severe PsA and
later combined to form TA199. NICE permits the use of sequential
biologics in RA, however switching between anti-TNFs in PsA is not
endorsed at present. Increasingly PsA patients who fail on 1st line anti-
TNF therapy due to inefficacy/adverse effects are left with no further
therapeutic options. Limited data from open label studies and
registries have confirmed the potential benefits of switching between
anti-TNFs. Our aim was to assess compliance with current NICE
guidance regionally and the outcome of patients who fail their 1st anti-
TNF drug.
Methods: A retrospective audit was conducted up to June 2012, to
include all PsA patients on a current anti-TNF in the north-west. Each
rheumatology department in the region was invited to participate. Data
were collected locally by a designated site coordinator, then analysed
centrally using Microsoft Excel 2011.
Results: Data on 548 patients were collected across 18 sites. Mean
age was 48 years (range 20–80 years), with 51% of patients being
female. Mean time from diagnosis to starting anti-TNF was 7.5 years.
80% commenced anti-TNFs after NICE guidance was introduced.
28% were on biologic monotherapy and 72% were on a concomitant
DMARD- of which 84% on MTX. Majority of patients were started on
adalimumab 1st line (64%), followed by etanercept (34%), infliximab
(2%) and golimumab (1%). At 12 weeks 74% of patients had an
adequate response however 24% of patients were not on their initial
anti-TNF at the time of the audit (reasons included: 41% secondary
inefficacy, 19% primary inefficacy, 26% intolerance, 4% pregnancy).
17% of all patients switched between anti-TNFs against NICE
guidance, with 3% switching between 3 and 4 biologics.
Subsequent lines of biologics included anti-TNFs but also rituximab
(n¼ 2), ustekinumab (n¼1) and tocilizumab (n¼ 1). 74% switched due
to inefficacy, 26% due to intolerance. Only 24% of switchers obtained
permission from their PCT; 4 patients regionally had an individual
TABLE 1. Nr-axSpA and AS baseline disease characteristics
Registries RCTs
GESPIC Kiltz ATLAS ABILITY-1 Haibel
All AS AS 5 years nr-axSpA 5 years AS nr-axSpA AS nr-axSpA nr-axSpA
n¼ 236 n¼ 119 n¼226 n¼ 56 n¼ 44 n¼ 315 n¼ 185 n¼ 46
Age, years 35.6 36.1 36.1 41.2 39.1 42.2 38.0 37.5
Female, % 36.0 34.5 57.1 23.2 68.2 25.1 54.6 54.3
HLA-B27þ, % 88.2 73.1 74.7 89.1 86.4 78.7 75.1 67.4
Symptom duration, years 5.2 3.0 2.6 12.8 9.4 – 10.1 7.5
Duration since diagnosis, years 2.8 1.7 1.7 7.5 5.0 10.6 2.9 –
BASDAI 0–10 4.0 4.0 3.9 4.2 3.6 6.3 6.5 6.3
Abnormal CRP, % 51.9 49.6 29.8 69.1 29.5 67.6 35.7 37.8
Total back pain, VAS 0–10 – – – – – 6.5 6.9 –
Total pain, VAS 0–10 5.0 4.8 4.8 4.7 4.0 _– 6.8 7.2
Patient Global Assessment of disease activity, VAS 0–10 5.0 5.0 4.9 4.6 4.0 6.3 6.8 6.6
Physician Global Assessment of disease activity, VAS 0–10 4.5 4.4 3.6 3.5 2.7 5.7 5.7 5.9
Values are the mean unless otherwise indicated. nr-axSpA: non-radiographic axial SpA.
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funding request rejected. Of the switchers, 52% of patients responded
to 2nd line biologic and a further 8% to 3rd line biologic; 19% were
non-responders, 2% intolerant and 19% were awaiting follow up to
assess response to switching at the time of the audit.
Conclusions: Every centre in the north-west participated, most sites
auditing all eligible patients representing an accurate reflection of
current practice. PCTs across the region varied significantly regarding
their policy on switching anti-TNFs in PsA. The results support the
effectiveness of switching and signify a need for updating current
national guidance to allow more therapeutic alternatives for the most
severely affected patients.
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